Nanexa
2.34
SEK
-6.77 %
NANEXA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
3 following
-6.77%
+83.53%
+48.57%
+161.74%
+90.24%
+92.59%
-36.59%
-74.64%
-71.4%
Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.
Read moreMarket cap
317.53M SEK
Turnover
1.14M SEK
Revenue
29.33M
EBIT %
-261.27 %
P/E
-
Dividend yield-%
-
Financial calendar
19.2
2025
Annual report '24
ShowingAll content types
Nanexa invites to a webcast to present the positive clinical data from NEX-22 once monthly GLP-1, liraglutide project published on last Friday
All Primary and Secondary endpoints met in Nanexa’s Phase I study of the one-month GLP-1 depot NEX-22
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools